Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses

Recruiting

Conditions: Erdheim-Chester Disease

First Posted Date: 2017-11-01

Last Posted Date: 2023-12-11

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 250

Registration Number: NCT03329274

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New YorK, New York, United States

Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors

Completed

Conditions: Metastatic Melanoma

Interventions: Behavioral: EuroQoL EQ-5D-3L
Behavioral: EORTC QLQ-C30
Other: PRO-CTCAE
Behavioral: Fatigue severity score questionnaire
Behavioral: The COST
Behavioral: Physician information

First Posted Date: 2017-10-31

Last Posted Date: 2020-12-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 107

Registration Number: NCT03326973

Locations: 🇺🇸
Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of the Neck
HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Interventions: Diagnostic Test: F-FMISO PET/CT Scan
Radiation: 30 Gy over 3 weeks
Drug: Cisplatin
Drug: Carboplatin
Drug: 5Fluorouracil
Radiation: Proton Therapy

First Posted Date: 2017-10-27

Last Posted Date: 2024-04-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 316

Registration Number: NCT03323463

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 7 locations

Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma

Phase 1

Terminated

Conditions: Mesothelioma

Interventions: Drug: pevonedistat
Drug: Pemetrexed and cisplatin

First Posted Date: 2017-10-24

Last Posted Date: 2024-05-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 9

Registration Number: NCT03319537

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Nassau, Uniondale, New York, United States

and more 5 locations

Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites

Phase 4

Active, not recruiting

Conditions: Smoking Cessation

Interventions: Drug: Nicotine Lozenge
Drug: Nicotine Replacement Therapy (NRT)
Behavioral: Motivational Interviewing (MI)
Behavioral: Message Framing
Other: saliva sample

First Posted Date: 2017-10-20

Last Posted Date: 2025-01-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 807

Registration Number: NCT03315910

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
WellStar Health System, LaGrange, Georgia, United States
🇺🇸
Maine Medical Center Cancer Institute, Scarborough, Maine, United States

and more 15 locations

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Phase 2

Active, not recruiting

Conditions: AL Amyloidosis
Multiple Myeloma

Interventions: Drug: Siltuximab
Behavioral: The M.D. Anderson Symptom Inventory (MDASI)

First Posted Date: 2017-10-19

Last Posted Date: 2024-11-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT03315026

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

Phase 1

Completed

Conditions: Breast Cancer
Prostate Cancer
Advanced Solid Tumors

Interventions: Drug: AZD5363
Drug: Enzalutamide
Drug: Fulvestrant

First Posted Date: 2017-10-16

Last Posted Date: 2023-05-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 12

Registration Number: NCT03310541

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer

Completed

Conditions: Thyroid Cancer

Interventions: Behavioral: Questionnaires

First Posted Date: 2017-10-03

Last Posted Date: 2023-07-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 186

Registration Number: NCT03300284

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Hartford Healthcare (Data Collection), Hartford, Connecticut, United States

and more 2 locations

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Early Phase 1

Completed

Conditions: Mantle Cell Lymphoma
Lymphoma

Interventions: Drug: BR-I (bendamustine, rituximab, ibrutinib)
Drug: VEN (Venetoclax)

First Posted Date: 2017-09-27

Last Posted Date: 2024-01-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT03295240

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: daratumumab
Drug: carfilzomib
Drug: lenalidomide
Drug: dexamethasone

First Posted Date: 2017-09-25

Last Posted Date: 2024-07-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 75

Registration Number: NCT03290950

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy